27 C
Vientiane
Tuesday, April 29, 2025
spot_img
Home Blog Page 714

Discover the Perfect Blend of European French Cheeses and Spices: A Culinary Adventure for Singaporean Palates

SINGAPORE, Jan. 23, 2025 /PRNewswire/ — Experience the ultimate fusion of flavors with French cheeses in a unique culinary campaign to captivate Singaporean food lovers.

 The Europe, Full of Character” campaign, sponsored by CNIEL (the French Dairy Board) and the European Union, explores French cheese recipes enriched with spices that resonate with Singapore’s diverse culinary heritage.

“French cow milk cheese is more than just food; it’s an experience. By blending these cheeses with Singaporean spices, we aim to inspire local chefs and home cooks to explore bold and creative culinary expressions,” says François Robin, French cheesemonger.

A Fusion of Heritage and Creativity

French cheeses, renowned for their quality and diversity, are celebrated for their versatility in pairing with ingredients from around the globe. This campaign spotlights how the finest cheeses from France—from creamy Camembert to nutty Comté and tangy Bleu d’Auvergne—can elevate traditional Singaporean dishes, creating exciting fusion recipes like:

  • Spiced Camembert Curry Dip: A rich, creamy dip infused with garam masala and chili, perfect for prawn crackers or naan.
  • Comté Laksa: A twist on the iconic dish with melted Comté lending a nutty depth to the coconut broth.
  • Bleu d’Auvergne Rendang: A daring pairing of Bleu d’Auvergne with traditional rendang spices, balancing bold flavors with creamy tanginess.

Singapore Roti John recipe with French Cheese
Singapore Roti John recipe with French Cheese

Interesting Facts About French Milk Cheeses

  1. Over 1,200 Varieties: France is home to an incredible range of cheese, each crafted with expertise and dedication.
  2. Aging brilliance: Many French cheeses, like Brie de Meaux and Comté, are aged to perfection, creating layers of flavor that develop over time.
  3. Sustainable practices: French dairy farms prioritize animal welfare and sustainable methods, ensuring high-quality milk for exceptional cheeses.
  4. Perfect pairings: French cheese pairs seamlessly with spices like star anise, turmeric, and cinnamon, offering a world of culinary possibilities.

Discover the Taste of France in Singapore

Through the campaign, Singaporeans can learn how to incorporate French cheese into their home cooking and elevate family meals, festive gatherings, and everyday moments.

 You can find HERE a lot of recipes, testimonies from Cheesemonger Francois Robin, videos and photos of our recent events.

Join us next year for the last year of the campaign and stay tuned on @cheesycharacters_sg for exclusive cooking demonstrations, recipe releases, giveaways and tasting events.

Join the Movement

Follow the Europe, Full of Character’ campaign on social media to discover unique recipes, cooking tips, and exciting collaborations with local chefs and food enthusiasts. Don’t forget to share your creations using @cheesycharacters_sg #FrenchCheeseSG #EuropeFullOfCharacter

#EnjoyItsFromEurope #EUagripromo

About CNIEL
CNIEL (Centre National Interprofessionnel de l’Economie Laitière) stands as a vital entity within the French dairy industry, committed to championing the interests of professionals in the field. Their mission revolves around the promotion, research, and innovation of the dairy sector, with a strategic focus on enhancing economic, technical, and social aspects. Through active promotion campaigns, research initiatives, market exploration, and educational programs, CNIEL strives to elevate the French dairy industry. Their vision encompasses a thriving and sustainable sector, celebrated for its quality, innovation, and contribution to a balanced and healthy diet.

CAMPAIGN FINANCED WITH AID FROM THE EUROPEAN UNION 
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them.

Sunway Medical Centre named in the inaugural Newsweek’s Asia’s Top Private Hospitals 2025 ranking

SUBANG JAYA, Malaysia, Jan. 23, 2025 /PRNewswire/ — Sunway Medical Centre, Sunway City (SMC), has been honoured in the inaugural Newsweek’s Top Private Hospitals 2025 ranking and recognised as the top hospital in Malaysia for four out of five procedures: knee surgery and knee replacement, shoulder surgery, cataract surgery, and eye refractive surgery.

(From left) Dato Lau Beng Long, Sunway Healthcare Group President; Dr Jeffrey Jaya Raj, Head of Orthopaedic Department, Sunway Medical Centre, Sunway City (SMC); Dr Peh Khaik Kee, Clinical Head of Ophthalmology, SMC; Dr Low Kwai Siong, Medical Director, SMC; Tan Mei Shin, Senior Director of Business Development & Corporate Communications; SMC; Choong Sui Ching, General Manager of Orthopaedic Services, SMC
(From left) Dato Lau Beng Long, Sunway Healthcare Group President; Dr Jeffrey Jaya Raj, Head of Orthopaedic Department, Sunway Medical Centre, Sunway City (SMC); Dr Peh Khaik Kee, Clinical Head of Ophthalmology, SMC; Dr Low Kwai Siong, Medical Director, SMC; Tan Mei Shin, Senior Director of Business Development & Corporate Communications; SMC; Choong Sui Ching, General Manager of Orthopaedic Services, SMC

Additionally, it is ranked 2nd in Asia for cataract surgery, and 3rd in Asia for refractive eye surgery. SMC is also featured in the top 10 of Asia’s ranking for hip surgery and hip replacement (6th); knee surgery and knee replacement (6th); and shoulder surgery (10th).

“We are honoured to be ranked among the best in Asia for key specialities such as orthopaedics and ophthalmology. It is a testament to our relentless pursuit of clinical excellence.

“The recognition also underscores the dedication of medical specialists and other healthcare professions in providing a high standard of multidisciplinary care and treatment to our Malaysian and international patients,” said Dato’ Lau Beng Long, President of Sunway Healthcare Group.

As Malaysia’s largest private quaternary hospital, SMC is the first hospital in Malaysia to obtain three major hospital-wide accreditations: Joint Commission International (JCI) Accreditation, The Gold Seal of Approval from the United States; the Australian Council on Healthcare Standards (ACHS); and the Malaysian Society for Quality in Health (MSQH).

The hospital offers 28 Centres of Excellence, supported by a diverse multidisciplinary team that provides holistic and personalised treatment.

Sunway Eye Centre, one of SMC’s Centres of Excellence, offers services across various subspecialties including cataract and refractive ophthalmology, cornea transplant, medical retinal and uveitis, glaucoma, oculoplastic ophthalmology, and paediatric ophthalmology.

SMC’s Orthopaedic Centre, together with Robotic Surgery and Minimally Invasive Surgery (MIS) Centre, have achieved remarkable milestones, especially in robotic hip and knee replacement surgeries, which earned recognition in the Malaysia Book of Records. This achievement underscores the centre’s expertise and unwavering commitment to innovation.

This latest rankings builds on SMC’s success in the Newsweek World’s Best Hospitals 2024 rankings, where it was named one of the top 250 hospitals globally. The hospital was also featured in Newsweek’s Best Specialist Hospitals Asia Pacific list for two consecutive years, 2023 and 2024.

SK hynix Announces 4Q24 Financial Results

  • Revenues for 2024 at 66.1930 trillion won, operating profit at 23.4673 trillion won, net profit at 19.7969 trillion won
  • Revenues for Q4 at 19.7670 trillion won, operating profit at 8.0828 trillion won, net profit at 8.0065 trillion won
  • Achieving best-ever quarterly and yearly performance with increased sales of AI memory products including HBM and eSSD
  • Company to affirm the possibility of achieving sustainable profit through differentiation of AI product competitiveness and profitability-oriented operation

SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ — SK hynix Inc. (or “the company”, www.skhynix.com) announced today that it recorded best-ever yearly performance with 66.1930 trillion won in revenues, 23.4673 trillion won in operating profit (with an operating margin of 35%), and 19.7969 trillion won in net profit (with a net margin of 30%).

Yearly revenues marked all-time high, exceeding the previous record in 2022 by over 21 trillion won and operating profit exceeded the record in 2018 during the semiconductor super boom.

* FY2022 Yearly Revenues: 44.6216 trillion won / FY2018 Yearly Operating Profit: 20.8437 trillion won

In particular, fourth quarter revenues went up by 12% to 19.7670 trillion won, operating profit up 15% to 8.0828 trillion won (with an operating margin of 41%) from the same period last year and net profit recorded 8.0065 trillion won (with a net margin of 41%).

SK hynix emphasized that with prolonged strong demand for AI memory, the company achieved all-time high result through world-leading HBM technology and profitability-oriented operation.

HBM continued its high growth in fourth quarter marking over 40% of total DRAM revenue and eSSD also showed constant increase in sales. With remarkable product competitiveness based profitability-oriented operation, the company established a stable financial condition which led to improved outcome.

Annual result of 2024 demonstrated memory company’s possibility of stable profit gain by supplying product in right time to meet customers’ needs. Especially, in which the memory sector is being transformed into a high-performance, high-quality market with growth of AI memory demand.

Based on the financial result, at the end of 2024, cash equivalent increased by 5.2 trillion won to 14.2 trillion won and debt decreased by 6.8 trillion won to 22.7 trillion won compared to the end of 2023, leading the significant improvement in the debt ratio and net debt ratio to 31% and 12% respectively.

SK hynix forecasts that the demand of HBM and high density server DRAM, which is essential in high performance computing, will continue to increase as the global big tech companies’ investment in AI servers grow and AI inference technology gains importance. In the consumer market, which inventory adjustment is expected, sales of PC and smartphones equipped with AI will expand and the market situation will pick up in the second half of the year.

Therefore, the company plans to expand HBM3E supply and develop HBM4 in right time to meet customers’ needs. With stable demand, the company aims to push for the transition to advanced process, necessary for the production of competitive DDR5 and LPDDR5. For NAND, as last year, the company plans to meet the market with profitability-oriented operation and flexible sales strategies.

SK hynix raised the annual fixed dividend by 25% to 1,500 won a share from 1,200 won and hiked total amount of the cash dividend to 1 trillion won annually. Along with the raise, the company decided to put aside 5% of the free cash flow, which was formerly included in the dividend policy, for enhancement of the financial structure.

“With significantly increased portion of high value-added products, SK hynix has built fundamental to achieve sustainable revenues and profits even in times of market correction.” said Kim Woohyun, Vice President and Chief Financial Officer (CFO) at SK hynix. “While maintaining the profitability-first commitment, the company will make flexible investment decisions in line with market situation.”

FY2024 Financial Results (K-IFRS)

*Unit: Billion KRW

FY24

YoY

FY23

Change

Revenues

66,193.0

32,765.7

102 %

Operating
Profit

23,467.3

-7,730.3

Turn to
profit

Operating
Margin

35 %

-24 %

59%p

Net Income

19,796.9

-9,137.5

Turn to
profit

4Q24 Financial Results (K-IFRS)

*Unit: Billion KRW

4Q24

QoQ

YoY

3Q24

Change

4Q23

Change

Revenues

19,767.0

17,573.1

12 %

11,305.5

75 %

Operating
Profit

8,082.8

7,030.0

15 %

346.0

2,236 %

Operating
Margin

41 %

40 %

1%p

3 %

38%p

Net Income

8,006.5

5,753.4

39 %

-1,379.5

Turn to
profit

※ Financial information of the earnings is based on K-IFRS

※ Please note that the financial results discussed herein are preliminary and speak only as of January 23, 2025. Readers should not assume that this information remains operative at a later time.

About SK hynix Inc.

SK hynix Inc., headquartered in Korea, is the world’s top tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”), flash memory chips (“NAND flash”) and CMOS Image Sensors (“CIS”) for a wide range of distinguished customers globally. The Company’s shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxemburg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

Bright Scholar Schedules Unaudited Financial Results for the First Quarter of Fiscal 2025 Ended November 30, 2024

CAMBRIDGE, England and FOSHAN, China, Jan. 23, 2025 /PRNewswire/ — Bright Scholar Education Holdings Limited (“Bright Scholar,” the “Company,” “we” or “our”) (NYSE: BEDU), a global premier education service company, today announced that it will release its unaudited financial results for the first quarter of fiscal 2025 ended November 30, 2024, on January 24, 2025, before the US market opens.

The Company’s management will host an earnings conference call at 7:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong Time) on January 24, 2025.

Dial-in details for the earnings conference call are as follows:

Mainland China:                  4001-201203
Hong Kong:                         800-905945
United States:                     1-888-346-8982
International:                       1-412-902-4272

Participants should dial-in at least 5 minutes before the scheduled start time and ask to be connected to the call for “Bright Scholar Education Holdings Limited.”

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://ir.brightscholar.com/.

A replay of the conference call will be accessible after the conclusion of the live call until January 31, 2025, by dialing the following telephone numbers:

United States Toll Free:   1-877-344-7529
International:                    1-412-317-0088
Replay Passcode:            6100559

About Bright Scholar Education Holdings Limited

Bright Scholar is a global premier education service Group. The Company primarily provides quality international education to global students and equips them with the critical academic foundation and skillsets necessary to succeed in the pursuit of higher education.

For more information, please visit: https://ir.brightscholar.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s business plans and development, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

IR Contact:
Email: BEDU@thepiacentegroup.com
Phone: +86 (10) 6508-0677/ +1-212-481-2050

Media Contact:
Email: media@brightscholar.com

Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

STUART, Fla., Jan. 23, 2025 /PRNewswire/ — Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable’s Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency.

Vitable’s enhanced primary care plan combines in-person and virtual primary care access with mental health programs, free prescription drugs, lab work, and care navigation for the entire household, all under a low monthly fee and $0 out-of-pocket cost for members. With their cost containment ability proven by numerous third-party actuarial firms and reinsurance carriers, our intention is to utilize Vitable’s DPC to provide competitively priced quotes within Health In Tech’s proprietary eDIYBS platform for networks and carriers under MARPAI’s self-funded health plan offerings. We expect Vitable’s high utilization and member satisfaction to contribute to reductions in healthcare costs.

“This collaboration exemplifies our commitment to revolutionizing healthcare access and affordability,” said Glenn Hillyer, Chief Growth Officer at Health In Tech. “By integrating Vitable’s hybrid DPC model – with their successful track record in effectively managing primary care and urgent care claims for self-funded and level-funded plans – with MARPAI’s self-funded health plans, and the streamlined process for which Health In Tech is known for, we are working to deliver competitive value and comprehensive care to our clients.”

Vitable’s hybrid DPC model seeks to ensure seamless access to primary care and mental health services, providing members with the flexibility and convenience of both in-home and virtual visits. This approach addresses the critical need for accessible and affordable healthcare, especially for the under- and uninsured workforce.

“We are excited to join forces with Health In Tech and MARPAI to bring our high-quality health plans at a significantly lower cost,” said Steven Baek, Head of Growth at Vitable. “Our commitment is to enhance member satisfaction and utilization while driving down healthcare costs.”

“We are excited to announce our collaboration with both Health In Tech and Vitable, two leaders in the employee benefits space,” said Ben Utz, Vice President of Strategic Accounts at Marpai. “Together, we hope to deliver smarter, seamless healthcare experiences that prioritize employee well-being, improve access to personalized care, and drive meaningful results for organizations.”

This competitive quote opportunity will be available through Health In Tech’s eDIYBS platform starting today.

About Health In Tech

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

About Vitable

Vitable offers a hybrid Direct Primary Care health plan for self-funded and level-funded groups, delivering easy access to high-quality primary care and mental health coverage to the under- and uninsured American workforce. Vitable membership includes in-home and virtual primary care visits, free prescriptions, labs, and mental health programs with no out-of-pocket cost for the members.

About Marpai, Inc.

Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna, industry leading Reference Based Pricing (RBP) solutions and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://www.ir.marpaihealth.com.

Forward-Looking Statements Regarding Health In Tech

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

Investor Contact

Investor Relations:
ir@healthintech.com

 

 

Pictor Biotech Inc. (d.b.a. SOLARBIOTECH), GPC Bio, and Eleszto Genetika Announce Strategic Unification

NORTON, Va., LA ROCHELLE, France and BUDAPEST, Hungary, Jan. 23, 2025 /PRNewswire/ — Today, SOLARBIOTECH, GPC Bio, and Eleszto Genetika proudly announced their acquisition and strategic unification under a single ownership.

This consolidation creates a vertically integrated Synthetic Biology and Biomanufacturing powerhouse, uniquely positioned to harness the disruptive potential of precision fermentation. By integrating decades of expertise, the unified organization will leverage the strength of each team to seamlessly advance Synthetic Biology innovation from ideation to commercial production.

The acquisitions bring together over 100 engineers, scientists, and seasoned biotech executives, marking a significant leap forward in the rapidly evolving biomanufacturing landscape. The unified organization is fully equipped to give clients unparalleled and seamless support in all stages of biomanufacturing, including microbial strain and bioprocess development, plant engineering, automation, construction, deployment, and large-scale operations. The coming months will involve further integrational activities to fully leverage the strength of the organization.

Strategic Relevance

The challenges of microbial strain engineering often hindered by restrictive intellectual property and the technical hurdles of scaling bioprocesses, have long impeded the faster development of synthetic biology products. By uniting these companies, we can directly address these challenges head-on, transforming the biomanufacturing landscape with the financial and operational support necessary for growth,” said Alex Berlin, CEO of Pictor Biotech Inc. (d.b.a. SOLARBIOTECH).

Zsolt Popsé, CEO of GPC Bio, added, “With nearly 20 years of experience in designing, engineering, automating, and deploying biomanufacturing equipment, we have delivered world-class facilities for leading biopharmaceutical companies such as Merck, Sanofi, and Millipore-Sigma, as well as major food and beverage companies like Cargill, Groupe Soufflet, and Lesaffre. The integration of GPC Bio with EG and SOLARBIOTECH places us in a unique position to mitigate risk and accelerate growth in the biomanufacturing space.

Lóránd Szabó, Managing Director of Eleszto Genetika Kft., stated, “Over the past two decades, we have developed hundreds of microbial strains for the production of biopharmaceuticals, nutraceuticals, and cosmeceuticals. By joining forces with Solar Biotech and GPC Bio, we can efficiently transition products from laboratory scale to commercial production, overcoming the typical hurdles faced by non-integrated organizations.”

Peter Rosholm, owner of EG, GPC Bio and Pictor Biotech (dba SOLARBIOTECH) emphasized: “I am fully committed to investing in and to accelerate the commercial development of sustainable biomanufacturing technologies. By combining SOLARBIOTECH, GPC Bio, and EG under one umbrella, we are uniquely positioning our teams to thrive in this rapidly growing sector. We have a strong, client-focused and diverse organization with very experienced management, and this commitment adds significant funding to the existing companies’ infrastructure.”

About the Companies

Executive Management of the three companies will continue to serve in their respective leadership roles. Peter Rosholm will exclusively serve the organization from an owner and investor capacity.

SOLARBIOTECH (“SBC”), based in Norton, VA, USA, offers world-class expertise in microbial and animal and plant cell precision fermentation and downstream processing across various scales. Leveraging 18 acres of industrial park infrastructure in Southwest Virginia, SBC consistently delivers innovative synthetic biology bioprocesses and products for its partners.

GPC Bio (“GPC”), headquartered in La Rochelle, France, specializes in the design, automation, software control, engineering, and fabrication of biomanufacturing equipment for the biopharmaceutical, food tech, and beverage industries. For nearly two decades, GPC Bio has delivered state-of-the-art systems to some of the biggest names in industrial biotech and biopharma.

Eleszto Genetika Kft. (“EG”), based in Budapest, Hungary, brings nearly two decades of expertise in R&D for advanced industrial microbial strains. EG’s portfolio includes microbial strains from engineered yeasts, bacteria, and filamentous fungi for producing a wide range of biopharmaceuticals, nutraceuticals, and cosmeceuticals, supported by cutting-edge infrastructure in the heart of the European Union.

For Further Information, Please Contact:

Altair Engineering Inc. Stockholders Approve Proposed Merger with Siemens

TROY, Mich., Jan. 23, 2025 /PRNewswire/ — Altair Engineering Inc. (“Altair“) (Nasdaq: ALTR), a global leader in computational intelligence, today announced that its stockholders voted at a special meeting to adopt the merger agreement with Siemens Industry Software Inc. (“Siemens Industry“), a subsidiary of Siemens AG (“Siemens AG“).

The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission (the “SEC“) on January 22, 2025.

As previously announced, under the terms of the merger agreement, Siemens Industry will acquire all of the outstanding shares of Altair’s common stock for $113.00 per share in cash. Upon completion of the transaction, Altair’s securities will no longer be listed on any public stock exchange.

About Altair

Altair is a global leader in computational intelligence that provides software and cloud solutions in simulation, high-performance computing (HPC), data analytics, and AI. Altair enables organizations across all industries to compete more effectively and drive smarter decisions in an increasingly connected world – all while creating a greener, more sustainable future. To learn more, please visit www.altair.com

About Siemens

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably. In fiscal 2024, which ended on September 30, 2024, the Siemens Group generated revenue of €75.9 billion and net income of €9.0 billion. As of September 30, 2024, the company employed around 312,000 people worldwide on the basis of continuing operations. Further information is available on the Internet at www.siemens.com.

Forward Looking Statements

This communication contains “forward-looking statements” within the Private Securities Litigation Reform Act of 1995. Any statements contained in this communication that are not statements of historical fact, including statements regarding the proposed transaction, including the expected timing and closing of the proposed transaction; Altair’s ability to consummate the proposed transaction; the expected benefits of the proposed transaction and other considerations taken into account by the Altair Board of Directors in approving the proposed transaction; the amounts to be received by stockholders and expectations for Altair prior to and following the closing of the proposed transaction, may be deemed to be forward-looking statements. All such forward-looking statements are intended to provide management’s current expectations for the future of Altair based on current expectations and assumptions relating to Altair’s business, the economy and other future conditions. Forward-looking statements generally can be identified through the use of words such as “believes,” “anticipates,” “may,” “should,” “will,” “plans,” “projects,” “expects,” “expectations,” “estimates,” “forecasts,” “predicts,” “targets,” “prospects,” “strategy,” “signs,” and other words of similar meaning in connection with the discussion of future performance, plans, actions or events. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict. Such risks and uncertainties include, among others: (i) the timing to consummate the proposed transaction, (ii) the risk that a condition of closing of the proposed transaction may not be satisfied or that the closing of the proposed transaction might otherwise not occur, (iii) the risk that a regulatory approval that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated, (iv) the diversion of management time on transaction-related issues, (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction, (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the common stock of Altair, (vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Altair to retain customers and retain and hire key personnel and maintain relationships with its suppliers and customers, (viii) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement, (ix) unexpected costs, charges or expenses resulting from the merger, (x) potential litigation relating to the merger that could be instituted against the parties to the merger agreement or their respective directors, managers or officers, including the effects of any outcomes related thereto, (xi) worldwide economic or political changes that affect the markets that Altair’s businesses serve which could have an effect on demand for Altair’s products and impact Altair’s profitability and (xii) disruptions in the global credit and financial markets, including diminished liquidity and credit availability, changes in international trade agreements, including tariffs and trade restrictions, cyber-security vulnerabilities, foreign currency volatility, swings in consumer confidence and spending, raw material pricing and supply issues, retention of key employees, increases in fuel prices, and outcomes of legal proceedings, claims and investigations. Accordingly, actual results may differ materially from those contemplated by these forward-looking statements. Investors, therefore, are cautioned against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Altair’s filings with the SEC, including the risks and uncertainties identified in Part I, Item 1A – Risk Factors of Altair’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001701732/000095017024018804/altr-20231231.htm ) and in Altair’s other filings with the SEC (which are available on Altair’s website at https://investor.altair.com/financials/quarterly-results). The list of factors is not intended to be exhaustive.

These forward-looking statements speak only as of the date of this communication, and Altair does not assume any obligation to update or revise any forward-looking statement made in this communication or that may from time to time be made by or on behalf of Altair.

Contacts:

Investor Relations:
Stephen Palmtag
+1 669-328-9111
spalmtag@altair.com 

Media Relations:
Jennifer Ristic
+1 216-849-3109
jristic@altair.com

Infinitus Honored as “China Top Employer” for Five Consecutive Years

GUANGZHOU, China, Jan. 23, 2025 /PRNewswire/ — On the evening of January 16, 2025, the annual “China Top Employers” list was announced. Infinitus secured the coveted title of “China Top Employer 2025” for the fifth year in a row.

Infinitus honored as "China Top Employer 2025"
Infinitus honored as “China Top Employer 2025”

In an environment characterized by constant technological progress, economic change and evolving social dynamics, organizations and individuals alike face myriad challenges. The recognition fully demonstrates Infinitus’ commitment to creating an outstanding workplace in the midst of these challenging circumstances. It also highlights the remarkable achievements that have been made in partnership with its employees. Below we take a closer look at the reasons why Infinitus was praised by the authorities in this year’s certification.

Revitalizing Corporate Culture and Enhancing Team Synergy

  • Our corporate culture permeates every aspect of team collaboration, fostering seamless integration.
  • Management takes the lead in cultural introspection through listening to employee feedback, acting on collective consensus, and unleashing the true potential of our cultural ethos.
  • Cultural ambassadors and workshops are crucial in preserving the authenticity and vitality of our practices, enriching our cultural narrative.
  • Through engaging cultural stories, animations, and workplace adornments, we ensure our culture is not only engaging but also unforgettable, captivating the eyes, minds, and hearts of our employees.

Elevating Learning and Development: Empowering Employees for Continuous Achievement

  • Infinitus champions the continuous learning and growth of its employees, urging them to actively embrace organizational transformation and seek opportunities for personal and professional growth.
  • The Infinitus Learning Season saw over 2,700 participants, collectively logging more than 5,000 hours of learning, enriching their knowledge and skills across various domains.
  • In alignment with strategic talent needs, initiatives like the internal mobility program energize our workforce, encouraging active participation in organizational developments and facilitating personal breakthroughs.
  • Geek contests and stories celebrate small successes, motivating a collective pursuit of excellence.

Fostering a Vibrant and Healthy Work Environment

  • Infinitus embraces healthy and joyful work practices, creating a fulfilling workplace experience that accompanies employees throughout their career journey through a multitude of engaging programs and activities.
  • Activities range from wellness drink tasting and spatial exploration games to work celebrations and family gatherings during Mid-Autumn festival, ensuring enjoyment at every stage of employment.
  • A variety of seasonal sports programs, including basketball, boxing, rock climbing, swimming, and ice skating, cater to every athletic interest.
  • Wellness days, mental health counseling platforms, and anti-fraud workshops provide a robust foundation for employee well-being and happiness.

The “China Top Employer 2025” certification serves as a testament to the recognition and encouragement for Infinitus’ unwavering dedication to talent development and employee career advancement. Looking ahead, Infinitus remains committed to fostering a sense of pride and identity among its employees, uniting to build a healthier and happier life for all.